Zoetis (ZTS) Confirms Bill Ackman Call; No Comment on Details of Conversation

Zoetis (ZTS) PT Raised at BofA/Merrill Lynch on Strong Fundamentals

BofA/Merrill Lynch analyst Robert Willoughby reiterated a Buy and boosted his price target on Zoetis Inc. (NYSE: ZTS) to $49.00 (from $41.00) on improving fundamentals with heightened conviction in its prospects in 2014 and beyond.

Willoughby noted Henry Schein, the largest global animal health distributor posted +8%... More

Allergan (AGN) Board Approves Amended Bylaws in Connection with Special Shareholders Meetin

Allergan (NYSE: AGN) announced that its Board of Directors has approved amendments to the Companys bylaws that streamline the process associated with calling a special meeting of stockholders. The Board determined to amend the bylaws after meetings with many of the Companys major stockholders and other governance organizations to solicit their input and perspectives. Following these meetings, the Board reached the conclusion that the benefits of certain provisions of the bylaws, as previously formulated, were outweighed by the associated administrative burdens. The amendments announced today underscore Allergans commitment to good corporate governance and... More

Pershing Square Capital Takes 8.3% Stake in Zoetis (ZTS)

In a 13D filing on Zoetis (NYSE: ZTS), Bill Ackman's hedge fund Pershing Square Capital disclosed a 8.3%, or 41,823,145 share, stake in the company. The firm did not hold shares at the end of the latest quarter ending September 30, 2014.

More from the 13D:

The Reporting Persons believe that the Issuers Common Stock is undervalued and is an attractive investment.

The Reporting Persons intend to engage in discussions with the Issuer and Issuers... More